论文部分内容阅读
目的 探讨新一代质子泵抑制剂兰索拉唑治疗消化性溃疡的临床疗效及对幽门螺杆菌（ＨＰ） 感染的根除率。方法 将１４５ 例经胃镜确诊为十二指肠球部溃疡病人随机分为２ 组，其中治疗组６８ 例，每日清晨空腹口服兰索拉唑３０ ｍｇ；对照组７７ 例，每日早晚２ 次口服雷尼替丁１５０ ｍｇ，４ 周为１ 疗程。疗程结束后全部复查胃镜观察溃疡愈合情况及ＨＰ感染情况。结果 治疗组６８ 例十二指肠球部溃疡愈合６６ 例，愈合率为９７．１％ ，ＨＰ根除率为６２．３％ （３８／６１） ；对照组７７ 例十二指肠球部溃疡愈合４８ 例，愈合率为６２．３％ ，ＨＰ根除率２８．６ ％（２０／７０），两者相比均有显著性差异（ Ｐ＜０ ．０１） 。结论 兰索拉唑治疗十二指肠球部溃疡的愈合率及ＨＰ感染根除率均明显优于雷尼替丁组，疗效确切。
Objective To evaluate the clinical efficacy of a new generation of proton pump inhibitor lansoprazole treatment of peptic ulcer and eradication rate of H. pylori (HP) infection. Methods One hundred and forty-five patients diagnosed as duodenal ulcer by gastroscope were randomly divided into two groups, including 68 cases in the treatment group. Each group was given lansoprazole 30 mg daily by fasting on an empty stomach. In the control group, 77 cases were treated with morning and evening twice a day Ranitidine 150 mg orally, 4 weeks for a course of treatment. After the end of treatment all the gastroscopy observed ulcer healing and HP infection. Results The treatment group of 68 patients with duodenal ulcer healing in 66 cases, the healing rate was 97.1%, HP eradication rate was 62.3% (38/61); the control group 77 cases of duodenal ulcer 48 cases, the healing rate was 62.3%, HP eradication rate of 28.6% (20/70), were compared to two significantly different (P <0 .01). Conclusion lansoprazole treatment of duodenal ulcer healing rate and the rate of HP infection eradication was superior to ranitidine and effective.